BioXL
WE develop innovative biopharma solutions for undertreated medical needs
Company Overview
Snapshot
Founded in October 2017, BioXL operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing innovative biopharma solutions for critical and underserved medical conditions.
Business overview
BioXL is a biopharmaceutical company dedicated to developing innovative solutions for critical and underserved medical conditions. Its core products include CancerPredict, a diagnostic test for breast cancer utilizing biomarkers and AI-powered software; CeaseCancer, an anti-cancer biologic drug for pancreatic cancer treatment; and NES Pharma, a drug treatment designed to prevent or slow dementia progression. The company serves the healthcare and life sciences sectors, with a focus on pharmaceuticals and addressing conditions prevalent in aging populations and women's health. BioXL operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is BioXL's primary focus?
- BioXL is a biopharma company focused on developing innovative solutions for critical and underserved medical conditions, including cancer and dementia.
- What is CancerPredict?
- CancerPredict is a diagnostic test developed by BioXL that uses biomarkers and AI-powered software to predict breast cancer development. It is designed to be integrated into current screening programs.
- What is CeaseCancer?
- CeaseCancer is an anti-cancer biologic drug developed by BioXL for pancreatic cancer treatment. It is an injectable drug with a unique mechanism of action that targets cancer cells without harming normal cells.
- What is NES Pharma?
- NES Pharma is a drug treatment developed by BioXL to prevent or slow dementia progression. It combines drug substances targeting glutamate excitotoxicity to achieve efficacy with minimal adverse effects.
- What other projects is BioXL working on?
- BioXL is also developing AMP-Bio, an antimicrobial drug to treat multi-drug resistant pathogens, and Marathon, a delivery system for use in Mitochondrial Replacement Therapy (MRT).